Clinical Scorecard: Unlocking Uveoscleral Outflow: A New Path Awaits Post-MIGS
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma with inadequate intraocular pressure (IOP) control post-MIGS |
| Key Mechanisms | Enhancement of natural uveoscleral outflow via creation of a cyclodialysis cleft using scleral spacers |
| Target Population | Pseudophakic patients with prior angle-based MIGS and moderate to severe glaucoma requiring multiple medications |
| Care Setting | Operative setting with anterior segment surgeons experienced in gonioscopy-guided procedures |
Key Highlights
- AlloFlo Uveo provides a bleb-free, durable alternative targeting the uveoscleral outflow pathway to extend success after MIGS.
- Procedure is minimally invasive, intuitive, and typically takes 5-10 minutes with a quick learning curve (3-5 cases).
- Clinical outcomes show significant and sustained IOP reduction with reduced medication burden and easy recovery.
Guideline-Based Recommendations
Diagnosis
- Identify patients with prior MIGS showing gradual loss of IOP control and increasing medication burden.
- Select pseudophakic patients with moderate to severe glaucoma progressing despite multiple medications.
Management
- Consider AlloFlo Uveo as an intermediate surgical option before conjunctival filtering procedures.
- Perform procedure to create and maintain a cyclodialysis cleft using scleral spacers to enhance uveoscleral outflow.
- Maintain angle-based surgical approach to preserve conjunctival integrity.
Monitoring & Follow-up
- Monitor IOP and visual field progression post-procedure to assess sustained pressure control.
- Evaluate medication reduction and ocular surface status during follow-up.
Risks
- Potential concerns include bleeding, retinal trauma, and postoperative IOP spikes, though early experience shows minimal trauma.
- Surgeons should be aware of and monitor for these complications during and after surgery.
Patient & Prescribing Data
Patients with moderate to severe glaucoma post-cataract surgery and MIGS, often on multiple medications with progressive disease.
AlloFlo Uveo can significantly reduce IOP and medication burden, with some patients becoming drop-free; it offers a new surgical option before resorting to bleb-forming procedures.
Clinical Best Practices
- Identify candidates early when IOP begins to rise after MIGS to optimize timing of AlloFlo Uveo intervention.
- Incorporate AlloFlo Uveo into the surgical armamentarium to enhance both trabecular and uveoscleral outflow pathways.
- Ensure surgeon familiarity with gonioscopy-guided anterior segment procedures to facilitate adoption and minimize complications.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.